54 related articles for article (PubMed ID: 34277416)
1. MYCN in Neuroblastoma: "Old Wine into New Wineskins".
Braoudaki M; Hatziagapiou K; Zaravinos A; Lambrou GI
Diseases; 2021 Oct; 9(4):. PubMed ID: 34842635
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
3. NLRR1 Is a Potential Therapeutic Target in Neuroblastoma and MYCN-Driven Malignant Cancers.
Takatori A; Hossain MS; Ogura A; Akter J; Nakamura Y; Nakagawara A
Front Oncol; 2021; 11():669667. PubMed ID: 34277416
[TBL] [Abstract][Full Text] [Related]
4. N-MYC promotes cell proliferation through a direct transactivation of neuronal leucine-rich repeat protein-1 (NLRR1) gene in neuroblastoma.
Hossain MS; Ozaki T; Wang H; Nakagawa A; Takenobu H; Ohira M; Kamijo T; Nakagawara A
Oncogene; 2008 Oct; 27(46):6075-82. PubMed ID: 18591937
[TBL] [Abstract][Full Text] [Related]
5. Tenascin-C: Form versus function.
Giblin SP; Midwood KS
Cell Adh Migr; 2015; 9(1-2):48-82. PubMed ID: 25482829
[TBL] [Abstract][Full Text] [Related]
6. Expression, refolding and spectroscopic characterization of fibronectin type III (FnIII)-homology domains derived from human fibronectin leucine rich transmembrane protein (FLRT)-1, -2, and -3.
Yang L; Hansen Falkesgaard M; Thulstrup PW; Walmod PS; Lo Leggio L; Krighaar Rasmussen K
PeerJ; 2017; 5():e3550. PubMed ID: 28698826
[TBL] [Abstract][Full Text] [Related]
7. Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma.
Satoh S; Takatori A; Ogura A; Kohashi K; Souzaki R; Kinoshita Y; Taguchi T; Hossain MS; Ohira M; Nakamura Y; Nakagawara A
Sci Rep; 2016 Sep; 6():32682. PubMed ID: 27604320
[TBL] [Abstract][Full Text] [Related]
8. Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
Pinto NR; Applebaum MA; Volchenboum SL; Matthay KK; London WB; Ambros PF; Nakagawara A; Berthold F; Schleiermacher G; Park JR; Valteau-Couanet D; Pearson AD; Cohn SL
J Clin Oncol; 2015 Sep; 33(27):3008-17. PubMed ID: 26304901
[TBL] [Abstract][Full Text] [Related]
9. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
10. NLRR1 enhances EGF-mediated MYCN induction in neuroblastoma and accelerates tumor growth in vivo.
Hossain S; Takatori A; Nakamura Y; Suenaga Y; Kamijo T; Nakagawara A
Cancer Res; 2012 Sep; 72(17):4587-96. PubMed ID: 22815527
[TBL] [Abstract][Full Text] [Related]
11. TIEG1 inhibits breast cancer invasion and metastasis by inhibition of epidermal growth factor receptor (EGFR) transcription and the EGFR signaling pathway.
Jin W; Chen BB; Li JY; Zhu H; Huang M; Gu SM; Wang QQ; Chen JY; Yu S; Wu J; Shao ZM
Mol Cell Biol; 2012 Jan; 32(1):50-63. PubMed ID: 22025675
[TBL] [Abstract][Full Text] [Related]
12. Neuroblastoma therapy: what is in the pipeline?
Verissimo CS; Molenaar JJ; Fitzsimons CP; Vreugdenhil E
Endocr Relat Cancer; 2011 Dec; 18(6):R213-31. PubMed ID: 21971288
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
